Bioventus announced enrollment of the first patients in its Phase 1 open-label, dose-escalation study of MOTYS (PTP-001). MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form.
The study is evaluating the safety and efficacy of MOTYS to treat osteoarthritis (OA) of the knee. Researchers are enrolling 20 patients with each patient receiving a single injection of PTP-001.
MOTYS offers an alternative to treatments like corticosteroids, hyaluronic acid injections and opioids to manage pain.
Alessandra Pavesio, Senior Vice President and Chief Science Officer, said, “This trial represents the first of multiple studies that Bioventus intends to conduct to demonstrate the safety and efficacy of our innovative biologic drug candidate designed to treat a prevalent, growing and debilitating condition like knee osteoarthritis.”
Bioventus announced enrollment of the first patients in its Phase 1 open-label, dose-escalation study of MOTYS (PTP-001). MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form.
The study is evaluating the safety and efficacy...
Bioventus announced enrollment of the first patients in its Phase 1 open-label, dose-escalation study of MOTYS (PTP-001). MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form.
The study is evaluating the safety and efficacy of MOTYS to treat osteoarthritis (OA) of the knee. Researchers are enrolling 20 patients with each patient receiving a single injection of PTP-001.
MOTYS offers an alternative to treatments like corticosteroids, hyaluronic acid injections and opioids to manage pain.
Alessandra Pavesio, Senior Vice President and Chief Science Officer, said, “This trial represents the first of multiple studies that Bioventus intends to conduct to demonstrate the safety and efficacy of our innovative biologic drug candidate designed to treat a prevalent, growing and debilitating condition like knee osteoarthritis.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
